neoplasm
• 6 of 51 founders develop leukemia, usually with short latent periods of 31-85 days after birth
|
• develop chronic myeloid leukemia-like phenotypes within 3 months of life
• mutants with leukemia show an increased percentage of mature myeloid cells and myeloid/lymphoid ratio in the peripheral blood and bone marrow resembling chronic myeloid leukemia
|
growth/size/body
• mutants with leukemia have low body weight
|
• mutants with leukemia exhibit splenomegaly
|
hematopoietic system
• about 20% increase in promyelocytes
• extreme expansion of myeloid cells at varying stages of maturation
|
• extreme expansion of myeloid cells at varying stages of maturation
|
• follicular architecture is damaged
|
• mutants with leukemia exhibit splenomegaly
|
• red pulp is infiltrated by myeloid cells, mainly myelocytes, metamyelocytes, and segmented forms
|
• all-trans-retinoic acid treatment does not induce bone marrow cells to differentiate as in controls
|
immune system
• about 20% increase in promyelocytes
• extreme expansion of myeloid cells at varying stages of maturation
|
• extreme expansion of myeloid cells at varying stages of maturation
|
• follicular architecture is damaged
|
• mutants with leukemia exhibit splenomegaly
|
• red pulp is infiltrated by myeloid cells, mainly myelocytes, metamyelocytes, and segmented forms
|
liver/biliary system
• focal infiltration of liver with myeloid precursors, however gross structure of the liver is unaffected
|
skeleton
• disruption of bone marrow trabeculae
|